麻豆传媒

Erica Ollmann Saphire, Ph.D. serves as President and CEO of the La Jolla Institute for Immunology. She is one of the world’s leading experts in pandemic and emerging viruses, such as Ebola, Marburg and Lassa. Dr. Saphire directs the Viral Hemorrhagic Fever Immunotherapeutic Consortium (VIC), an NIH-funded Center of Excellence in Translational Research. The VIC unites 43 previously competing academic, industrial and government labs across five continents to understand which antibodies are most effective in patients and to streamline the research pipeline to provide antibody therapeutics against Ebola, Marburg, Lassa and other viruses. Dr. Saphire's research explains, at the molecular level, how and why viruses like Ebola and Lassa are pathogenic and provides the roadmap for developing antibody-based treatments. Her team has solved the structures of the Ebola, Sudan, Marburg, Bundibugyo and Lassa virus glycoproteins, explained how they remodel these structures as they drive themselves into cells, how their proteins suppress immune function and where human antibodies can defeat these viruses. A recent discovery revealed why neutralizing antibodies had been so difficult to elicit against Lassa virus, and provided not only the templates for the needed vaccine, but the molecule itself: a Lassa surface glycoprotein engineered to remain in the right conformation to inspire the needed antibody response. This molecule is the basis for international vaccine efforts against Lassa.
Dr. Saphire is the recipient of numerous accolades and grants, including the Presidential Early Career Award in Science and Engineering presented by President Obama at the White House; the Gallo Award for Scientific Excellence and Leadership from the Global Virus Network; young investigator awards from the International Congress of Antiviral Research, the American Society for Microbiology, American Society for Biochemistry and Molecular Biology, and the MRC Centre for Virus Research in the United Kingdom; the Investigators in the Pathogenesis of Infectious Disease Award from the Burroughs Wellcome Fund, and the Surhain Sidhu award for the most outstanding contribution to the field of diffraction by a person within five years of the Ph.D. Dr. Saphire has been awarded a Fulbright Global Scholar fellowship from the United States Department of State and a Mercator Fellowship from the German research foundation, Deutsche Forschungsgemeinschaft, to develop international collaborations around human health and molecular imaging through cryoelectron microscopy.
Dr. Saphire received a B.A. in biochemistry and cell biology and ecology and evolutionary biology from Rice University in Houston, Texas, and a Ph.D. in molecular biology from Scripps Research. She stayed on at Scripps Research as a Research Associate to conduct postdoctoral research and rose through the ranks to become a Professor in the Department of Immunology and Microbiology. In early 2019, Dr. Saphire joined La Jolla Institute for Immunology to establish a molecular imaging facility for cryo-electron microscopy (cryo-EM) at the Institute. The extremely detailed images produced by cryo-EM reveal precisely how essential mechanisms of the immune system operate.

Dr. Larry Corey is an internationally renowned expert in virology, immunology and vaccine development, and the former president and director of the Fred Hutchinson Cancer Research Center in Seattle. For more than four decades, he has led some of the most significant advances in medicine, including the development of safe and effective antivirals for herpes, HIV and hepatitis infections. An international expert in the design and testing of vaccines, he is helping to formulate a global, strategic response to COVID-19.

Earlier this year, he responded to the sudden emergence of COVID-19 by redirecting his energies to speed the development of antiviral medications and vaccines against SARS-CoV-2, the virus responsible for the pandemic. He is building strategic collaborations among academic institutions, government health leaders and the pharmaceutical industry to test future COVID-19 vaccines and find ways to manufacture and distribute enough doses to immunize as many as 4 billion people.

Dr. Corey is drawing on his expertise as a co-founder, in 1998, of the HIV Vaccine Trials Network. Headquartered at Fred Hutch in Seattle, it is the world鈥檚 largest publicly funded collaboration focused on development of vaccines to prevent HIV/AIDS.

Dr. Corey's teaching and mentoring interests include virology, viral immunology and development of novel therapies for viral infections. His current research projects include:

- Spatial and functional characterization of tissue resident immune responses at the site of herpesvirus or HIV infection
- Development of immunotherapies for HSV and HIV infection; including CAR T cells for treatment for HIV infection
- Spatial dynamics and function of adoptively transferred or vaccine induced T cells
- Characterization of tissue-based memory B cells and the role antibody effector responses play in chronic viral infections
- Use of monoclonal antibodies for the prevention of viral infections

In addition to his role as president and director emeritus at Fred Hutch, Dr. Corey is a member of the Center's Vaccine and Infectious Disease, Clinical Research, and Public Health Sciences Divisions.  He is also a Professor, Medicine and Laboratory Medicine at the University of Washington, and Principal Investigator at the HIV Vaccine Trials Network (HVTN). 

Dr. Garc铆a-Sastre is a Professor in the Department of Microbiology and Director of the Global Health and Emerging Pathogens Institute of Icahn School of Medicine at Mount Sinai in New York. For the past 25 years, his research interest has been focused on the molecular biology of influenza viruses and several other negative-strand RNA viruses. During his post-doctoral training in the early 1990s, he developed, for the first time, novel strategies for expression of foreign antigens by a negative-strand RNA virus, influenza virus. He has made major contributions to the influenza virus field, including 1) the development of reverse genetics techniques allowing the generation of recombinant influenza viruses from plasmid DNA, (studies in collaboration with Dr. Palese); 2) the generation and evaluation of negative-strand RNA virus vectors as potential vaccine candidates against different infectious diseases, including malaria and AIDS, and 3) the identification of the biological role of the non-structural protein NS1 of influenza virus during infection: the inhibition of the type I interferon (IFN) system. His studies provided the first description and molecular analysis of a viral-encoded IFN antagonist among negative-strand RNA viruses.  These studies led to the generation of attenuated influenza viruses containing defined mutations in their IFN antagonist protein that might prove to be optimal live vaccines against influenza. His research has resulted in more than 480 scientific publications and reviews. Dr. Garc铆a-Sastre is the director of the Center for Research on Influenza Pathogenesis (CRIP), one of the five NIAID funded Centers of Excellence for Influenza Research and Surveillance. He was among the first members of the Vaccine Study Section and member of the Virology B Study Section of NIH. In addition, he has served for 5 years as Editor of Journal of Experimental Medicine, is Editor of PLoS Pathogens, Journal of Virology and Virus Research, and member of the Editorial Board of Virology, Vaccine, NPJ Vaccines and Influenza and Other Respiratory Diseases.  He is a member of the scientific advisory board of Keystone Symposia. He has been a co-organizer of the international course on Viral Vectors (2001), held in Heidelberg, Germany, sponsored by Federation of European Biochemical Societies (FEBS), and of the first Research Conference on Orthomyxoviruses in 2001, held in Texel, The Netherlands, sponsored by the European Scientific Working Group on Influenza (ESWI). He has also been a co-organizing of the 7th International Society for Vaccines meeting in 2013, and of Keystone Meetings in 2014 on Respiratory Virus Pathogenesis and in 2017 on Interferons. His publication in Science on the reconstruction and characterization of the pandemic influenza virus of 1918 has been awarded the distinction of the paper of the year 2005 by Lancet. In 2005, he became a Fellow of the American Academy of Microbiology, and in 2009, he received the Beijerink Professorship from the National Academy of Sciences of the Netherlands. In 2011, he has been elected President of the International Society for Vaccines, for 2014 and 2015. In 2017, he has been elected a fellow of the Royal Academy of Pharmacy in Spain.

Dr. Rebecca Ellis Dutch is聽a Professor and Chair of the Department of Molecular and
Cellular Biochemistry at the University of Kentucky, and currently leads the COVID-19
Unified Research Experts Alliance team focused on biomedical and clinical issues related to
the pandemic for the university. Becky received a BS in Biochemistry and a BS in
Microbiology from Michigan State University in 1986. As a Churchill Scholar, she then
completed a M.Phil. degree in Biochemistry from Cambridge University, focusing on plant
biochemistry. She received her Ph.D. in Biochemistry from Stanford University in 1994,
working with Dr. I. Robert Lehman on recombination in herpes simplex virus. Becky then
moved to studies of viral glycoproteins in RNA viruses for her postdoctoral training at
Northwestern University/HHMI with Dr. Robert Lamb. She joined the faculty of the University
of Kentucky in 2000. Her research, which has resulted in continuous NIH funding since 2001
and numerous other grants, manuscripts, and presentations focuses on emerging RNA
viruses, with a particular emphasis on viral entry, assembly, and spread.聽 Dr. Dutch was a
2015-2016 University Research Professor in recognition of her outstanding research efforts.
Dr. Dutch teaches at both the undergraduate and graduate level and has twice been named
a finalist for the Provost鈥檚 Outstanding Teacher award. She is also highly committed to the
training and mentoring of young scientists and has served as the primary mentor for 19
Ph.D. students, 4 MD/Ph.D. students, five postdoctoral scholars, and 28 undergraduate
researchers. Dr. Dutch is an editor for Journal of Virology (where she also serves as the
Spotlight editor), Plos Pathogens, and mSphere. She has been a member of numerous grant
review panels, including serving as a standing member of the NIH VIRB and MID study
sections. She also served as the elected President of the American Society for Virology from
2016-2017.

Dr. Amy Moore is the Director of Science and Research at GO2 Foundation. Dr. Amy C. Moore is a PhD-trained virologist and cancer researcher and has spent over a decade working on large statewide and multi-institution initiatives in cancer and vaccines. She currently serves as Director of Science & Research for the GO2 Foundation for Lung Cancer and also works closely with GO2 Foundation's sister organization, the Addario Lung Cancer Medical Institute (ALCMI), to build research capacity in emerging areas of concern to the lung cancer community.  

Because of her virology training and position as a leader in the advocacy community, Dr. Moore has become a highly sought-after expert to discuss the intersection of lung cancer and COVID-19. Since early March, she has participated in over half a dozen panel discussions, webinars, and interviews with leading groups such as IASLC, CURE, US 麻豆传媒 & World Report to discuss the threat COVID-19 presents to patients with lung cancer and how we can mobilize research to understand this risk. 

Montaner studies the mechanisms of disease in HIV-1 infection and cancer, exploring new strategies to boost the natural function of the immune system in order to combat viral-associated disease or cancer progression.

Montaner obtained his D.V.M., Veterinary Medicine from Kansas State University in 1989 and his D.Phil. in Experimental Pathology from University of Oxford, Oxford, U.K., in 1995. He joined The Wistar Institute in 1995 as an assistant professor and was promoted to professor in 2007.

Professor Runstadler joined the Department of Infectious Disease & Global Health in 2017. Working at the host-pathogen-environmental interface, the Runstadler laboratory studies how emerging virus, specifically influenza, is maintained, transmitted and evolves in reservoir or intermediate animal hosts. A major part of this work is directed at understanding how both host and viral factors may influence the risk of viral spillover into new hosts, including humans. Dr. Runstadler is working with collaborators to bridge the gap between studies of disease surveillance and disease ecology with a molecular and comparative understanding of pathogenesis, immune response and evolution. His current research is particularly focused on understanding genotype-phenotype relationships of the influenza virus, the role of diverse hosts and environments, and the interspecies movement of virus to the emergence of disease in new populations.
Prior to joining the faculty at the Cummings School, Dr. Runstadler was a faculty member at both the University of Alaska Fairbanks with the Institute of Arctic Biology and the Massachusetts Institute of Technology in the Division of Comparative Medicine. Dr. Runstadler received an undergraduate degree from Stanford University and his DVM and PhD in Genetics from the University of California, Davis. Prior to beginning his own lab at UAF, Dr. Runstadler was a postdoctoral fellow in the Center for Companion Animal Health under Dr. Neils Pedersen at the University of California, Davis.

Rowley earned his B.A. at the University of Warwick in England, which introduced him to the fascinating aspects of microbiology and biochemistry. After working in the food safety industry, he began a doctorate program studying the biology of bacterial viruses and the molecular mechanisms of the phiC31 integrase protein at the University of Aberdeen in Scotland.

Upon relocating to Texas, he studied the molecular mechanisms of a recombinase from a parasitic yeast plasmid and the replication of viruses that infect fungi and primates. He continued this work as a postdoc at the Biofrontiers Institute at Colorado University Boulder, CO. These projects gave  Rowley a broad base of expertise used techniques from molecular biology, biochemistry and evolution, that are applied in his current research projects.